help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Podbesek, R.
Right arrow Articles by Zanelli, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Podbesek, R.
Right arrow Articles by Zanelli, J. M.

Endocrinology, Vol 112, 1000-1006, Copyright © 1983 by Endocrine Society


ARTICLES

Effects of two treatment regimes with synthetic human parathyroid hormone fragment on bone formation and the tissue balance of trabecular bone in greyhounds

R Podbesek, C Edouard, PJ Meunier, JA Parsons, J Reeve, RW Stevenson and JM Zanelli

The adult greyhound was found to be similar to adult man with respect to kinetic and histomorphometric indices of calcium metabolism. The relationship between trabecular bone tissue balance and the pattern of human PTH fragment 1-34 (hPTH 1-34) administration by daily injections or continuous sc infusions was investigated in this model and the results compared to those from a clinical trial of hPTH 1-34 in involutional osteoporosis (peptide administration by single daily injections). In the dogs, the daily injection regime elevated plasma levels of immunoreactive hPTH 1-34 for no more than 4 h/day. The greyhounds so treated showed significantly increased indices of bone formation (surface osteoid, plasma alkaline phosphatase activity, and skeletal accretion rate of calcium) and resorption (number of osteoclasts, resorption surfaces). Iliac trabecular bone volume increased significantly, as it did in the patients. The infusions did not significantly increase the trabecular bone volume or the 47Ca accretion rate, two parameters which increased in parallel in dogs and patients treated successfully by daily injections. The osteoclastic surfaces, however, were clearly increased by continuous infusions, while the increases in the osteoblastic surfaces were less statistically significant. Since hPTH 1-34 may inhibit osteogenesis in Friedenstein chambers, it is possible that the increased osteoblastic activity induced by the daily injection regime in trabecular bone is dependent on the noncontinuous nature of the PTH stimulus.


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
F. Joseph, B. Y. Chan, B. H. Durham, A. M. Ahmad, S. Vinjamuri, J. A. Gallagher, J. P. Vora, and W. D. Fraser
The Circadian Rhythm of Osteoprotegerin and Its Association with Parathyroid Hormone Secretion
J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3230 - 3238.
[Abstract] [Full Text] [PDF]


Home page
J Bone Joint Surg BrHome page
D. G. Little, M. Ramachandran, and A. Schindeler
The anabolic and catabolic responses in bone repair
J Bone Joint Surg Br, April 1, 2007; 89-B(4): 425 - 433.
[Abstract] [Full Text] [PDF]


Home page
JBJSHome page
Y. M. Alkhiary, L. C. Gerstenfeld, E. Krall, M. Westmore, M. Sato, B. H. Mitlak, and T. A. Einhorn
Enhancement of Experimental Fracture-Healing by Systemic Administration of Recombinant Human Parathyroid Hormone (PTH 1-34)
J. Bone Joint Surg. Am., April 1, 2005; 87(4): 731 - 741.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
S. Bonadonna, A. Burattin, M. Nuzzo, G. Bugari, E. A. Rosei, D. Valle, N. Iori, J. P Bilezikian, J. D Veldhuis, and A. Giustina
Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects
Eur. J. Endocrinol., February 1, 2005; 152(2): 199 - 205.
[Abstract] [Full Text] [PDF]


Home page
J Am Acad Orthop SurgHome page
G. R. Madore, P. J. Sherman, and J. M. Lane
Parathyroid Hormone
J. Am. Acad. Ortho. Surg., March 1, 2004; 12(2): 67 - 71.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. H. Mikulec, L. Holloway, R. E. Krasnow, H. Javitz, G. E. Swan, T. Reed, R. Marcus, and D. Carmelli
Relationship of Endogenous Sex Hormones to Coronary Heart Disease: A Twin Study
J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1240 - 1245.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
K. A Cappuzzo and J. C Delafuente
Teriparatide for Severe Osteoporosis
Ann. Pharmacother., February 1, 2004; 38(2): 294 - 302.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. K. W. Chan, S.-C. Tiu, K.-L. Choi, C.-H. Choi, A. P. S. Kong, and C.-C. Shek
Increased Bone Mineral Density in Patients with Chronic Hypoparathyroidism
J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3155 - 3159.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. M. Ahmad, J. Thomas, A. Clewes, M. T. Hopkins, R. Guzder, H. Ibrahim, B. H. Durham, J. P. Vora, and W. D. Fraser
Effects of Growth Hormone Replacement on Parathyroid Hormone Sensitivity and Bone Mineral Metabolism
J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2860 - 2868.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. Lotinun, J. D. Sibonga, and R. T. Turner
Triazolopyrimidine (Trapidil), a Platelet-Derived Growth Factor Antagonist, Inhibits Parathyroid Bone Disease in an Animal Model for Chronic Hyperparathyroidism
Endocrinology, May 1, 2003; 144(5): 2000 - 2007.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
C. Crandall
Parathyroid Hormone for Treatment of Osteoporosis
Arch Intern Med, November 11, 2002; 162(20): 2297 - 2309.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
R. M. Neer, C. D. Arnaud, J. R. Zanchetta, R. Prince, G. A. Gaich, J.-Y. Reginster, A. B. Hodsman, E. F. Eriksen, S. Ish-Shalom, H. K. Genant, et al.
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
N. Engl. J. Med., May 10, 2001; 344(19): 1434 - 1441.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. Tetradis, O. Bezouglaia, and A. Tsingotjidou
Parathyroid Hormone Induces Expression of the Nuclear Orphan Receptor Nurr1 in Bone Cells
Endocrinology, February 1, 2001; 142(2): 663 - 670.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Brommage, C. E. Hotchkiss, C. J. Lees, M. W. Stancill, J. M. Hock, and C. P. Jerome
Daily Treatment with Human Recombinant Parathyroid Hormone-(1-34), LY333334, for 1 Year Increases Bone Mass in Ovariectomized Monkeys
J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3757 - 3763.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
X.-P. Yu and S. Chandrasekhar
Parathyroid Hormone (PTH 1-34) Regulation of Rat Osteocalcin Gene Transcription
Endocrinology, August 1, 1997; 138(8): 3085 - 3092.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
A. Toromanoff, P. Ammann, L. Mosekilde, J. S. Thomsen, and J.-L. Riond
Parathyroid Hormone Increases Bone Formation and Improves Mineral Balance in Vitamin D-Deficient Female Rats
Endocrinology, June 1, 1997; 138(6): 2449 - 2457.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Hollnagel, D. Schroder, and G. Gross
Domain-specific Gene Activation by Parathyroid Hormone in Osteoblastic ROS17/2.8 Cells
J. Biol. Chem., September 6, 1996; 271(36): 21870 - 21877.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1983 by The Endocrine Society